Abstract

The effects of a 21-day live high-train low (LHTL) on hemoglobin mass (Hbmass) and iron demand including the erythropoietin (EPO)-erythroferrone (ERFE)-hepcidin axis and routine iron markers were investigated. Fifteen female endurance athletes completed either 21-day LHTL in normobaric hypoxia (2500 m, ~18 h·day−1) (INT, n = 8) or lived and trained in normoxia (CON, n = 7). Hbmass and resting blood were collected before and after the intervention. An additional blood sample was collected on Day 6 for INT. 21-day LHTL increased Hbmass 3.8% in INT (p < 0.001). EPO increased 35.6% from Day 0 to Day 6 in INT (p = 0.037) and then decreased 42.4% from Day 6 to Day 21 (p = 0.019). In INT, no changes were detected in ERFE or hepcidin, and from the routine iron markers only serum transferrin receptor increased from Day 0 to Day 21 (13.9%, p = 0.013). In CON, no changes were detected in Hbmass or iron markers. In INT, Hbmass and ferritin were positively associated (Day 0 to Day 6, p = 0.005). Thus, hepcidin and ERFE may not provide additional information regarding iron demand following 6- or 21-day LHTL compared to routine iron markers. The relationship between Hbmass and ferritin indicates that adequate ferritin levels are needed during hypoxia to support hematological adaptations.

Document Type

Journal Article

Date of Publication

12-1-2025

Volume

13

Issue

24

PubMed ID

41420382

Publication Title

Physiological Reports

Publisher

American Physiological Society

School

School of Medical and Health Sciences

Funders

Finnish Ministry of Education and Culture (OKM/2/626/2023) / Seppo Säynäjäkangas Science Foundation (12/2023) / Kainuu Regional Fund of the Finnish Cultural Foundation (5/2024)

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Comments

Kuorelahti, T., Ihalainen, J. K., Linnamo, V., Badenhorst, C., Kettunen, O., & Mikkonen, R. (2025). “Live high‐train low” induced changes in hemoglobin mass and the erythropoietin‐erythroferrone‐hepcidin axis in female endurance athletes. Physiological Reports, 13(24), e70707. https://doi.org/10.14814/phy2.70707

Share

 
COinS
 

Link to publisher version (DOI)

10.14814/phy2.70707